å»è¬åå ¬è¡šãããæŽå¯
ã¬ã¹ãã©ãããŒã«åžå Ž - æŽå¯ ã¬ã¹ãã©ãããŒã«ã¯ããã©ããã€ãã®ã°ã«ãŒãã«å±ãããã©ãããŒã«ã§ãããã¬ã¹ãã©ãããŒã«ã¯ãæ§ã ãªæ€ç©ã现èãçèãªã©ã®ç åèã«äŸµããããšãã«èªç¶ã«åæããããã¡ã€ãã¢ã¬ãã·ã³ã§ãããã¬ã¹ãã©ãããŒã«ã¯ãèµ€ãããŠãããŒãããããã«ãŒããªãŒãæ¡ã®å®ãã©ãºããªãŒããŠãŒã«ãªãããŠããªã©ãããŸããŸãªæ€ç©ãæå®ã«å«ãŸããŠãããã¬ã¹ãã©ãããŒã«ã¯ãå»è¬åãåç²§åãæ é€è£å©é£åã«åºãå©çšãããŠããã ã¬ã¹ãã©ãããŒã«ã¯ããããå¿è¡ç®¡ç³»çŸæ£ãç³å°¿ç ãç¥çµç³»çŸæ£ãªã©ã®æ§ã ãªçŸæ£ãæ²»çã»ç®¡çããç¹æ§ãæã£ãŠãããããè£œè¬æ¥çã§åºãå¿çšãããŠãããåç²§åæ¥çãæ é€è£å©é£åæ¥çã§ã¯ã... ãã£ãšèŠã
Diclofenacã¯åžå ŽèŠæš¡ãšäºæž¬ãããã â 2026 â 2033幎ã°ããŒãã«Diclofenacãããåžå ŽèŠæš¡ã¯è©äŸ¡ããããšæšå®ãããŸã 2026幎ã®USD 1.1åã§ãUSD 1.9åã«éããèŠèŸŒã¿ 2033幎ã2026幎ãã8.1%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º 2033幎é ãããã£ãŒã«Diclofenacã®ãããã¯ãšåœ¢æããã話é¡ã®çã¿ã®è»œæžãããã¯ãã§ã éã¹ããã€ãã®ççæå¶ã®è¬å€(NSAID)ã®diclofenacãèšèšããŸãã 屿çãªçã¿ãççãããã³musculoskeletalæ¡ä»¶ãæ±ãã ãããã®ãããã¯ç®ãéããŠå¶åŸ¡ãããè¬å€ã®è§£æŸãæäŸããŸããæžããŸã ... ãã£ãšèŠã
Betaxolåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«ã»ãã¿ããœãŒã« åžå ŽèŠæš¡ã¯ç±³ãã«1.8ã§è©äŸ¡ããããšæšå®ããã 2026 åç±³ãã«ã2033 åç±³ãã«ã«éããèŠèŸŒã¿ 2026幎ïœ2026幎ã«ãããŠ8.1%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎ããããã£ãŒã«Betaxol ã®åžå Žã®äž»èŠãªé転è ã¯å¢å ã® prevalence ãå«ãã§ããŸã ã°ã©ãŠã³ãããã³æ¥åé«è¡å§ãèåã®äžççãªäººå£ã«ãã£ãŠé転ããã ã¹ã¯ãªãŒã³é¢é£ã®ç®ã®ç·åŒµãå¢å ããã æé·ã®çºçç é«è¡å§ã®ãããªå¿è¡ç®¡ã®ç¶æ ã¯æŽã«å šèº«ãæ¯ããŸã ããŒã¿ãããã«ãŒã®èŠæ±ã çŒç§ã±ã¢ãžã®ã¢ã¯ã»ã¹ãæ¡å€§ ãã倧ãã蚺... ãã£ãšèŠã
Erythromycin åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«ã»ãšãªã¹ããã€ã·ã³ åžå ŽèŠæš¡ã¯ç±³ãã«ã§è©äŸ¡ããããšæšå®ããã 2026幎ã«1å15åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2033幎ãŸã§ã«1.87åç±³ãã«ã«éããèŠèŸŒã¿ 2026幎ãã6.5%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎ããããã£ãŒã«erythromycinã®åžå Žã¯äžæã®åªå é äœã«ãã£ãŠé転ãããŸã 现èã®äŒæãç¹ã«åŒåžç®¡ã®ãç®ããã³æ§çã« æå¹ãªãã¯ãã©ã€ããèŠæ±ãç¶ããéä¿¡ãããäŒæ æçç©è³ªã æçç©è³ªã®æµæã®å¢å ããµããŒãããŸãã ãšãªã¹ããã€ã·ã³ãæ®ã£ãŠãã代æ¿ãŸãã¯çµã¿åããçæ³ã®å¿ èŠæ§ é¢é£ãã... ãã£ãšèŠã
æªæ§ã¢ã·ãããæ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎äžçã®æªæ§Ascitesã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯ã§ãããšæšå®ãããŸã 2026幎ã«1åç±³ãã«ã«çžåœããUSD 2.75ã«éããèŠèŸŒã¿ 2033幎(æå20幎)ã9.6%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º 2026幎ïœ2033幎ãããã£ãŒã«æªæ§Ascitesã®åŠçœ®ã®åžå Žã¯äžæã«ãã£ãŠé転ãããŸã åµå·£ãèèãèãããã³èµèãªã©ã®çã®èå»¶ ç, äžè¬çã«è ¹éšã®æµäœèç©ã«ã€ãªããã æ¡çšæ å ± å é²çã«ããäžççãªããã®è² æ ãšé·æã«ãããæ£è ã®çå è «çåŠçæ³ã¯ãæªæ§ã®ããé«ãçºççã«è²¢ç®ããŠããŸã æ³å®äºäŸ ç·©åã±ã¢ããã³æ¹åããã質ã®ã... ãã£ãšèŠã
èè±çæ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2026 - 2033幎äžçã®Blepharitisã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯ã§ãããšæšå®ãããŸã 2026幎ã®USD 1.3åã§è©äŸ¡ãããUSD 2.1ã«éããèŠèŸŒã¿ 2033幎10æãååç©ã®å¹Žéæé·ç(CAGR)ã7.2%å¢ 2026幎ïœ2033幎ãããã£ãŒã«èè±çã®åŠçœ®ã®åžå Žã¯äžæã®åvalenceã«ãã£ãŠé転ãããŸã æ ¢æ§çŒé害ããã©ã€ã¢ã€çå矀ã®çºççã®å¢å ãããã³ çŒçŒè¡çããã³çŒç§ã®å¥åº·ã®é«ããããæèã ãšã€ãžã³ã° èè±çãé¢é£çŒã«ææãªäººå£ æ¡ä»¶ã¯ãåžå Žæé·ãæ¯ããŸãã 蚺æã®é²æ© æšççæ³ã®æè¡ãããŠéçºããå«ã åŠæ¹è¬ããµãã¯ã¹ã¯ã©ããããã³å ... ãã£ãšèŠã
å»ç廿£ç©ç®¡ç åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«å»ç廿£ç©ç®¡ç åžå ŽèŠæš¡ã¯æšå®ããã 2026幎ã®USD 15.8åã§è©äŸ¡ãããUSD 27.3ã«éããèŠèŸŒã¿ 2033幎(æå40幎)ã«å¢æ®ç(CAGR)ã8.4%å¢ 2026幎ïœ2033幎ãããã£ãŒã«å»ç廿£ç©ç®¡çåžå Žã¯å¢å ã«ãã£ãŠé転ãããŸã ç é¢ã®å ¥é¢ã«äŒŽããã«ã¹ã±ã¢å»æ£ç©ã®çºç äžçåå°ã®å»çã€ã³ãã©ã®æŽåãšæ®å ææç®¡çãšå³ããæ¿åºã®æèã®æ¡å€§ çç©å»åŠå»æ£ç©ã®å®å šãªåŠåã®ããã®èŠåã¯éèŠãªèŠå ã§ã æ¯æã®èŠæ±ã ææãšæ ¢æ§ã®èå»¶ã«äžæ çŸæ£ã¯ãé©åãªå»æ£ç©åŠçã®å¿ èŠæ§ãããã«åŒ·åããŸãã æ±æããã³ç°å¢ã®å±éºã... ãã£ãšèŠã
ãªã¡ãã©ãŸãŒã«ã®äžçåžå Ž - é žå³ã®ç®¡ç ãªã¡ãã©ãŸãŒã«ã¯ãäžè¬çã«åŠæ¹ããããããã³ãã³ãé»å®³è¬ïŒPPIïŒã§ãããèé žãæžå°ãããããªã¡ãã©ãŸãŒã«ã¯ãèé£ééæµçïŒGERDïŒã«äŒŽãèžããããã®ä»ã®çç¶ã®æ²»çè¬ãšããŠèŠå¶åœå±ããæ¿èªãããŠããããªã¡ãã©ãŸãŒã«ã¯ãã³ããæ§é£éçïŒèé žã«ããé£éæå·ïŒã®æ²»çä¿é²ã«ã䜿çšãããã ãªã¡ãã©ãŸãŒã«ã¯ãã¢ã¢ãã·ã·ãªã³ãã¯ã©ãªã¹ããã€ã·ã³ãªã©ã®æçç©è³ªãšçµã¿åãããŠããããªèã«ããæœ°çã®æ²»çã«äœ¿çšãããã ãªã¡ãã©ãŸãŒã«ã®äžçåžå ŽèŠæš¡ã¯2017幎ã«26å6,840äžç±³ãã«ãšè©äŸ¡ãããäºæž¬æéïŒ2018幎ïœ2026幎ïŒã®CAGRã¯5.2%ãšäºæ³ãããŠ... ãã£ãšèŠã
å¯çè«ã¯ã¬ã³ãºåžå Žã補åã¿ã€ãå¥ïŒããŒãå¯çè«ã¯ã¬ã³ãºè£œåãå»è¬åæå¯çè«è£œåãæ é€è£å©é£åããããã¯ã¹ããã³é å補å€ïŒãã¢ããªã±ãŒã·ã§ã³å¥ïŒè žå å¯çè«ç®¡çãæ¶ååšã®å¥åº·ãµããŒããäžè¬çãªãŠã§ã«ãã¹ããã³äºé²ã±ã¢ãããã³ç£å»çšéïŒãæµéãã£ãã«å¥ïŒè¬å±ããã³ãã©ãã°ã¹ãã¢ãã¹ãŒããŒããŒã±ããããã³ãã€ããŒããŒã±ãããå°éå¥åº·åºãããã³ãªã³ã©ã€ã³å°å£²ïŒãå°çå¥ (åç±³ãã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
æµ·æŽãªã¡ã¬3åžå ŽããœãŒã¹å¥ïŒéæ²¹ããªãã¢ãæ²¹ãè»é¡æµ·æŽæ²¹ãªã©ïŒã圢æ å¥ïŒããªã°ãªã»ãªãããšãã«ãšã¹ãã«ããªã³è質ãªã©ïŒãçšéå¥ïŒæ é€è£å©é£åãå»è¬åãæ©èœæ§é£åããã³é£²æãä¹³å çšæ é€ãåç©æ é€ïŒãæµéãã£ãã«å¥ïŒè¬å±ããã³ãã©ãã°ã¹ãã¢ãã¹ãŒããŒããŒã±ããããã³ãã€ããŒããŒã±ãããå°éåºã ãªã³ã©ã€ã³å°å£²)ãå°çå¥ (åç±³ãã©ãã³ã¢ã¡ãªã«ããšãŒããããã¢ãžã¢å€ªå¹³æŽãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
å°å èåŸ ã®ç²Ÿç¥çæ²»çåžå Ž - æŽå¯åŠåš äžã®çºäœ(äž»ã«ãã-malãšããŠç¥ããã)ã¯ãæäººãããé »ç¹ã«èµ·ãããšããèŠãããŸãã 4æ³ãã7æ³ãŸã§ã®å°å æ¬ ä¹ã®çºäœãå§ãŸããŸãã 幎霢ã4æ³ãã8æ³ã«ãªããŸã§ã¯ããŸããŸããã äžæ¥äž10ïœ100åããã¯ãã¬ãã·ãŒãšããŠç¥ããããã»ã€ãŸã¬ã¹ãã¯ãæ°åçºçããŸãã ã»ã€ãŸã¬ã¹ã¯ãçºäœã®æ§è³ªã«å¿ããŠãå žåçã§å žåçãªæ¬ åŠã®çºäœç©ã«åããããŸãã ããã€ãã®ä»ã®ç æ°ã®çç¶ã¯ããã€ç ã«äŒŒãŠããããã«ããã€ç ã蚺æããããšã¯å°é£ã§ããããšã蚌æããŸãã äžéšã®ãããã³ã«ã¯ãçºäœã®çºçæ¥ãæéãããã³ããç°¡åãªèšºæã®ããã®è©³çްãªèª¬æã®æ¥èšãç¶æãããªã©ã®æ£è ã«åŸã... ãã£ãšèŠã
ã·ã¯ã«ãœããåžå Ž - æŽå¯ã·ã¯ã«ãœããã¯ãåŒåžå°é£ãèžã®å ããå鳎ãããã³æäººããã³å°å ã®åæ¯ã«ãã£ãŠåŒãèµ·ããããå³ãäºé²ããããã«äœ¿çšãã12æ³ä»¥äžã§ãã ããã¯å®¹æãªåŒåžãå¯èœã«ããæ°éã®èšåŒµããã³èç«ã¡ãæžããããã«ã³ã«ãã³ã¹ããã€ãã®è¬ç©ã®ã¯ã©ã¹ãšããŠåããŸãã Ciclesonideã¯ãšãŒããŸã«ããã³éŒ»ã®ã¹ãã¬ãŒã§æ¥ãéåžž2æ¥2ååžå ¥ããå¿ èŠããããŸãã åŒåžãå鳎ãå³ã®æ¥ãªãšããœãŒããå«ãåæ¯ã®æ»æãé²ãã®ã«åœ¹ç«ã¡ãŸããåºçãããç ç©¶ææ ã¢ã¹ã 2015幎10æã«ã¢ã¡ãªã«ã®AAFA(AAFA)ããå€§æ°æ±æãæ¢åã®åæ¯çç¶ãæªåãããå¯èœæ§ãããããšãæããã«ããã åããœãŒã¹ã«... ãã£ãšèŠã
Calciphylaxis æ²»çåžå Ž â ã€ã³ãµã€ãCalciphylaxisãŸãã¯Calcific Uremic Arteriolopathy(CUA)ã¯ãéææ£è ã«ãããå¿è¡ç®¡æ¡åŒµã®æãå³ãã圢æ ã§ãã ããã¯å°ããåšèŸºå®¹åšã®ç³ç°åã«ãã£ãŠå§ãŸããããã«ããã£ã§åºãããŸãã ãŸããã«ã«ã·ãã£ã©ã·ããã«èŠããã§ãã人ã ã¯ã«ã«ã·ãŠã 代è¬ã®äžåè¡¡ãæã£ãŠããŸããããã¯ãæçµçã«åè硬åçã®è¡æ ã®åœ¢æã«ã€ãªããã«ã«ã·ãŠã ãåŒãèµ·ãããŸãã è¡æ¶²ååºã¯èèªçµç¹ãç®èãé žçŽ ãæ é€ã奪ãããå¯èœæ§ããããŸããåœç«ç ç©¶éçºæ³äººãã€ãªãã¯ãããžãŒæ å ±ã»ã³ã¿ãŒ(NCBI)2014å ±åæžã«æ²èŒãããããŒã¿ã«ãã... ãã£ãšèŠã
ã°ããŒãã«ã»ããªããã¬ãªã³åžå Ž â ã°ããŒãã«ã»ã€ã³ãµã€ãGonadotropin è§£æŸã®ãã«ã¢ã³ (GnRH) ã®ã¢ãŽãã¹ã㯠estrogens ãã倧ããå®å šããã³å¹åã®ãããããã£ãŒã«ããã³å»åŠã®å»å¢ãéæããããŸããŸãªçæ³éã®æã¢ã³ããã²ã³ããããŸãã ããã«ãGnRHã¢ãŽãã¹ãã®äœæŸåºè£œå€ã¯ãæ£è ã®æè»æ§ãæäŸããçæŽ»ã®è³ªãåäžãããæçµçã«ã³ã¹ããåæžããŸããã»ãšãã©ã®å Žåãåç«è ºããã¯ãã¹ãã¹ããã³ãã«ã¢ã³ãå¢å ãããããšã§é²è¡ããŸãã ããã«, ãã¹ãã¹ããã³ã®çç£ã¯ãæè¡çã«çŸäžžãé€å»ãããã培åºçã«åæ¢ããããšãã§ããŸã è¬ç©çæ³ãåãåãã Triptorelinã¯Gn... ãã£ãšèŠã
ãããµã€ã¯ãªã³å¡©é žå¡©åžå Žãå€åœ¢å¥ïŒã«ãã»ã«ãé å€ã泚å°è£œå€ãå±æè£œå€ïŒãçšéå¥ïŒãããæ²»çãçŽ°èææçæ²»çãé¢ç¯ãªãŠãããªã©ïŒãæµéãã£ãã«å¥ïŒç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ã ã¢ããªã«)... ãã£ãšèŠã
ã¬ããã³ãã³åžå Žãå€åœ¢å¥ïŒã«ãã»ã«ãé å€ãçµå£æ¶²ãªã©ïŒãçšéå¥ïŒç¥çµå æ§çŒçããŠããããããããèçå矀ïŒRLSïŒãªã©ïŒãæµéãã£ãã«å¥ïŒç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«ïŒ... ãã£ãšèŠã
æ²»çåžå Ž - æŽå¯èçãŸãã¯æªãåŒåžã¯ãéèŠãªå¿ççèŠçãåŒãèµ·ããå¯èœæ§ãããäžè¬çãªåé¡ã§ãã æ²»çã«ã¯å€ãã®æœåšçãªåå ãšæ²»çããããŸãã æ¯åšç ã®å¢æ®ã¯ãæ¯åšç ããã³æ¯åšç åŸãæ¯åšç ãæ±ãã人ã ã®éã§ã®äž»ãªçç±ã®äžã€ã§ãã è¯å¥œãªå£è è¡çãç¶æããããšã¯ãçœè¡çãæžããããã®æè¯ã®æ¹æ³ã§ãã ããã²ã³ãã¬ã¹ã¯ãããã°ã©ãã£ãŒãBANAãã¹ããβ-ã¬ã©ã¯ããŒãŒãã¹ããªã©ãããŸããŸãªããã€ã¹ããã¹ãã§ããªã¿ã€ãºãæ€ç¥ã§ããŸãã Halimeterè£ çœ®ã¯ãBANAãã¹ããçœå 现èã«ãã£ãŠçæãããç¹å®ã®é µçŽ ã®ã¬ãã«ã枬å®ããç¡«é»ã®äœã¬ãã«ãæ€åºããŸãã ã¬ã¹ã¯ãããã°ã©ãã£ãŒãã¹ãã¯ãžã¡ãã«... ãã£ãšèŠã
èé£ééæµçïŒGERDïŒããã³è朰çã»è žæœ°çã¯ããã®çœ¹æ£çã®å¢å ã«äŒŽããå»çé¢ä¿è ã®åŒ·ãé¢å¿ãéããŠãããGERDã¯äžè¬çãªå¥åº·åé¡ã§ãããæ·±å»ãªå䜵çãåŒãèµ·ããããã®èšºæãšæ²»çã«ã¯è«å€§ãªå»çè²»ãããããGERDã«é¢é£ããæãé »ç¹ã«èгå¯ããã2ã€ã®çç¶ã¯èžçŒããšèé žã®éæµã§ãããéåžžãåžè²©ã®å¶é žå€ããããã³ãã³ãé»å®³å€ãH-2åå®¹äœæ®æå€ãªã©ãèé žã®äœçšã匱ããããé žã®ç£çãé»å®³ããããã«äœ¿çšãããã ã©ãããžã³ã¯ãã¹ã¿ãã³H2æ®æè¬ã§ãèé£ééæµçïŒGERDïŒã®æ²»çã«é©å¿ããããåžè²©è¬ïŒOTCïŒãšåŠæ¹è¬ã®äž¡æ¹ãå ¥æå¯èœã§ãããã©ãããžã³ã¯èé žã®åæ³ãæå€§12æéæžå°ãããããŸããã©ãããž... ãã£ãšèŠã